Monoclonal Antibodies for Waldenström Macroglobulinemia

Andres Dominguez; Efstathios Kastritis; Jorge J Castillo

doi:10.1016/j.hoc.2018.05.010

Monoclonal Antibodies for Waldenström Macroglobulinemia

Hematol Oncol Clin North Am. 2018 Oct;32(5):841-852. doi: 10.1016/j.hoc.2018.05.010. Epub 2018 Jul 21.

Authors

Andres Dominguez¹, Efstathios Kastritis², Jorge J Castillo³

Affiliations

¹ Department of Internal Medicine, Fundación Valle del Lili, CES University, Cali, Colombia.
² Department of Clinical Therapeutics, National and Kapodistrian University, Athens, Greece.
³ Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Mayer 221, Boston, MA 02215, USA. Electronic address: jorgej_castillo@dfci.harvard.edu.

PMID: 30190022
DOI: 10.1016/j.hoc.2018.05.010

Abstract

For the last 2 decades, anti-CD20 monoclonal antibodies have revolutionized the treatment of patients with B-cell lymphomas. These agents have shown efficacy when used as single agents and also have improved response and survival rates when added to chemotherapy. Monoclonal antibodies are safe and effective as well in patients with Waldenström macroglobulinemia (WM). The purpose of this article is to review the mechanism of action of monoclonal antibodies and to discuss current clinical data supporting their use in patients with WM. This review focuses on retrospective and prospective studies and clinical trials on anti-CD20 antibodies, anti-CD38 antibody, and anti-CXCR4 antibody.

Keywords: Mechanism of action; Monoclonal antibodies; Treatment; Waldenström macroglobulinemia.

Publication types

Review

MeSH terms

Antineoplastic Agents, Immunological / immunology
Antineoplastic Agents, Immunological / therapeutic use*
Humans
Waldenstrom Macroglobulinemia / drug therapy*
Waldenstrom Macroglobulinemia / immunology
Waldenstrom Macroglobulinemia / pathology

Substances

Antineoplastic Agents, Immunological